1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Parkinson’s Disease Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Parkinson’s Disease Therapeutics Market, by Drug Class
8.1.1 Levodopa/Carbidopa
8.1.1.1. Market Revenue and Forecast
8.1.2. Dopamine Agonists
8.1.2.1. Market Revenue and Forecast
8.1.3. Adenosine A2A Antagonist
8.1.3.1. Market Revenue and Forecast
8.1.4. COMT Inhibitors
8.1.4.1. Market Revenue and Forecast
8.1.5. MAO-B Inhibitors
8.1.5.1. Market Revenue and Forecast
8.1.6. Glutamate Antagonist
8.1.6.1. Market Revenue and Forecast
8.1.7. Others
8.1.7.1. Market Revenue and Forecast
9.1. Parkinson’s Disease Therapeutics Market, by Route of Administration
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast
9.1.2. Subcutaneous
9.1.2.1. Market Revenue and Forecast
9.1.3. Transdermal
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. Parkinson’s Disease Therapeutics Market, by Patient
10.1.1. Adult
10.1.1.1. Market Revenue and Forecast
10.1.2. Pediatric
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class
11.1.2. Market Revenue and Forecast, by Route of Administration
11.1.3. Market Revenue and Forecast, by Patient
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class
11.1.4.2. Market Revenue and Forecast, by Route of Administration
11.1.4.3. Market Revenue and Forecast, by Patient
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class
11.1.5.2. Market Revenue and Forecast, by Route of Administration
11.1.5.3. Market Revenue and Forecast, by Patient
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class
11.2.2. Market Revenue and Forecast, by Route of Administration
11.2.3. Market Revenue and Forecast, by Patient
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class
11.2.4.2. Market Revenue and Forecast, by Route of Administration
11.2.4.3. Market Revenue and Forecast, by Patient
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class
11.2.5.2. Market Revenue and Forecast, by Route of Administration
11.2.5.3. Market Revenue and Forecast, by Patient
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class
11.2.6.2. Market Revenue and Forecast, by Route of Administration
11.2.6.3. Market Revenue and Forecast, by Patient
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class
11.2.7.2. Market Revenue and Forecast, by Route of Administration
11.2.7.3. Market Revenue and Forecast, by Patient
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class
11.3.2. Market Revenue and Forecast, by Route of Administration
11.3.3. Market Revenue and Forecast, by Patient
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class
11.3.4.2. Market Revenue and Forecast, by Route of Administration
11.3.4.3. Market Revenue and Forecast, by Patient
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class
11.3.5.2. Market Revenue and Forecast, by Route of Administration
11.3.5.3. Market Revenue and Forecast, by Patient
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class
11.3.6.2. Market Revenue and Forecast, by Route of Administration
11.3.6.3. Market Revenue and Forecast, by Patient
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class
11.3.7.2. Market Revenue and Forecast, by Route of Administration
11.3.7.3. Market Revenue and Forecast, by Patient
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class
11.4.2. Market Revenue and Forecast, by Route of Administration
11.4.3. Market Revenue and Forecast, by Patient
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class
11.4.4.2. Market Revenue and Forecast, by Route of Administration
11.4.4.3. Market Revenue and Forecast, by Patient
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class
11.4.5.2. Market Revenue and Forecast, by Route of Administration
11.4.5.3. Market Revenue and Forecast, by Patient
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class
11.4.6.2. Market Revenue and Forecast, by Route of Administration
11.4.6.3. Market Revenue and Forecast, by Patient
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class
11.4.7.2. Market Revenue and Forecast, by Route of Administration
11.4.7.3. Market Revenue and Forecast, by Patient
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class
11.5.2. Market Revenue and Forecast, by Route of Administration
11.5.3. Market Revenue and Forecast, by Patient
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class
11.5.4.2. Market Revenue and Forecast, by Route of Administration
11.5.4.3. Market Revenue and Forecast, by Patient
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class
11.5.5.2. Market Revenue and Forecast, by Route of Administration
11.5.5.3. Market Revenue and Forecast, by Patient
12.1. Cerevel Therapeutics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Hallamshire Physiotherapy Ltd
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Olatec Therapeutics
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Biotech Ltd
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Teva Pharmaceutical Industries Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck & Co., Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. GlaxoSmithKline plc. (GSK)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AbbVie, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Acorda Therapeutics, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
